SPK Outcome by Induction Therapy

For SPK MMF+Tac recipients’ antibody therapy, the 1-year GSR was highest, 90%, for non-depleting antibodies. Differences were small for the remaining antibody groups, 83%-89%, but they were significant (p<0.0005) (Figure 25). 

Figure 25

Previous page / Next page / Index